The Extraordinary General Meeting in IRRAS AB (publ) (the “Company”) has been held on 13 October 2023 and in particular the following resolution was made.
Resolution on issue of new shares
The General Meeting resolved to increase the Company’s share capital by a maximum of SEK 10,147,945.20 through a new issue of a maximum of 338,264,840 ordinary shares in accordance with the proposal from shareholder IR Holding Bidco Inc. (“IR Holding”).
The new shares may, with deviation from the shareholders’ preferential right, only be subscribed for by IR Holding, with the obligation for the subscriber to make payment for subscribed shares by way of set-off against loans amounting to SEK 60,000,000 plus accrued interest as of 12 September 2023 of SEK 887,671. The subscription price is SEK 0.18 per ordinary share.
Subscription must take place no later than 14 October 2023. The set-off will be considered executed immediately in connection with subscription of the new shares.
For more information, please contact:
President and Chief Executive Officer
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).